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Abstract
This review discusses the concepts and meth-
ods for assessing patient adherence to treat-
ment, as applied to both epidemiological and 
clinical approaches within real health care 
practices. For the epidemiological approach, 
the assessment must be as accurate as possible. 
Self-reported questionnaires are the most fea-
sible option in most circumstances, but most 
demonstrate low sensitivity combined with 
high specificity. We suggest that self-reported 
outcomes, where feasible, can increase the sen-
sitivity for non-adherence of these question-
naires. In the clinical approach an accurate 
distinction between adherents and non-adher-
ents is less useful. For the health provider, it is 
more important to be aware of the particular 
situation that each patient is currently expe-
riencing with his/her treatment. Self-reported 
questionnaires applied in clinical settings can 
help the health provider to form an objective 
opinion. In any event, the patient-provider 
dialogue is still the best approach to assess pa-
tient adherence as well as to deliver good care.
Patient Compliance; Chronic Disease; Evalua-
tion of Results of Therapeutic Interventions
Introduction
Good outcomes from chronic diseases largely 
depend on the degree of patient adherence to 
treatment. Many studies have shown that some 
degree of non-adherence occurs universally, in 
rich and poor countries alike, and is even seen in 
life-threatening diseases 1,2.
Large variations have been reported in the ex-
tent of non-adherence in individual patients and 
populations. In addition, studies have presented 
different concepts of adherence as well as differ-
ent measurements, without necessarily explain-
ing how these criteria interplay.
This is a free review aiming to discuss con-
cepts and methodological approaches for assess-
ing adherence, applied at both epidemiological 
and clinical contexts within real health care prac-
tices. Our motivation to write it was based on dis-
cussions we have had in our research group on 
adherence which bring together epidemiologists 
and clinicians. We searched the PubMed and 
SciELO databases to select studies that discuss 
different concepts and methods for assessing ad-
herence to chronic diseases. Most search results 
focused on reviews, but original papers were also 
included. Further references were selected from 
the bibliographies of cited papers.
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Measuring adherence: different 
definitions (but same methodology)
The concepts that are most commonly used are 
“compliance” and “adherence”. Compliance was 
defined as the extent to which a person’s behav-
ior coincides with medical or health recommen-
dations 3.
This definition became popular in the late 
1970s, and was considered to be less judgmental 
compared with other terms that classified pa-
tients as “recalcitrant”, “careless” or “irresponsi-
ble”. The concept led to patients that were not fol-
lowing treatment being considered as a scientific 
problem which could be potentially studied and 
addressed 4. However, many studies have criti-
cized this concept, both for its coercive connota-
tion as well as the fact that it reduces the issue to 
a matter of patient obedience 5,6,7.
Adherence was defined as the extent to which 
a person’s behavior corresponds with agreed rec-
ommendations from a health care provider 8.
The notion of adherence proposes an alli-
ance relationship, whereby therapeutic guid-
ance should be agreed upon between patient 
and health professional, thus recognizing partial 
autonomy of the patient with regard to how treat-
ment is followed 8.
Many studies have discussed both notions. 
This includes some who consider compliance as 
a dimension of adherence 9, those who “advo-
cate” one concept or another 10,11, those who use 
the terms interchangeably 12, and those who pro-
pose new notions attempting to overcome the 
limitations attributable to both compliance and 
adherence 13.
This debate, however, does not seem to have 
significantly affected empirical studies. Indeed 
these have frequently employed both terms, irre-
spective of the methodology used 14. This “theo-
retical indifference” appears not to have occurred 
by chance. Studies measuring adherence are es-
sentially epidemiological studies, in other words, 
aimed at population contexts. In these settings 
it is of little importance whether the adherent 
groups are “obedient” or “autonomous”. The key 
focus is on accurately measuring the number of 
adherents. After all, the end goal is to understand 
the problem from an epidemiological point of 
view, in so far as determining the adherence rate 
in the group under study. In this context, the title 
by Baril 15 (p. 13) seems quite fitting: “Observance, 
adherence, compliance... different words for better 
therapeutic results”.
This discussion takes on a different meaning 
in a clinical context, as will be discussed. Indeed, 
we shall seek to discuss some methodological 
issues involved in getting highest accuracy and 
greatest explanatory value from studies assessing 
adherence in epidemiological contexts.
Addressing adherence in epidemiological
contexts: seeking better accuracy
The majority of studies have used an acceptable 
rate of doses taken/prescribed or even general 
behavioral patterns of patients in relation to the 
medication as carelessness/forgetfulness.
Methods that quantify medication taken over 
a period of time allow for several continuous 
measurements as well as mean values. However, 
the majority of studies establish a cut-off point that 
represents an acceptable limit of non-adherence. 
The cut-off point is generally based on prior 
studies which have compared other methods 
and takes into account the acceptable clinical 
response for each disease. Thus for hypertension, 
“adherents” are considered as those that take at 
least 80% of prescribed medicines 16, while for 
AIDS treatment most studies have adopted 95% 
or more 17.
Different cut-off points obviously lead to dif-
ferent quantitative values of adherence. For ex-
ample, a study in hypertension which defines ad-
herent patients as those who take at least 80% of 
their medication and detect some 70% of adher-
ence, will report a lower percentage of adherent 
individuals upon adopting a stricter stance, ac-
cepting only those taking 95% of the prescribed 
dose 18.
Questionnaires seeking to estimate patterns 
of adherence behavior need to establish arbitrary 
cut-off points in defining non-adherent sub-
jects 19. Depending on the response to one or 
more questions, an individual shall be catego-
rized as non-adherent, thereby establishing the 
frequency of non-adherent individuals in a given 
group.
Patient self-reports through structured inter-
views are the most used options in observational 
studies due to their ease of application and low 
cost. Self-report measures should be assessed on 
the basis of their validity and electronic moni-
toring can be used as a reference standard. Pill 
counting, which is easy to apply and low cost, 
can also be used as standard although it pres-
ents more accuracy problems than electronic 
monitoring 20.
An important criticism concerning question-
naires used in epidemiological studies regards 
the conditions under which they are applied. 
Firstly, there is the issue of why questionnaires 
focus on undesirable behavior and why patients 
do not feel at ease answering these within the 
care facility they attend. Nevertheless, it should 
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be recognized that some measures traditionally 
viewed as more objective, such as manual pill 
counting or electronic monitoring may also not 
guarantee reliable results: pills may be discarded 
and even electronic chips on bottles can be tam-
pered 1,21,22. Therefore a self-report conducted 
through a well designed questionnaire in a con-
fidential interview has been considered a useful 
measure of adherence 23,24.
Moreover many self-reported questionnaires 
have provided reliable adherence measurements. 
This has been observed in studies on AIDS 25,26,27, 
hypertension 28,29 and immunosuppressant 
therapy 30.
In addition to obtaining different adher-
ence rates, the correlation amongst the various 
measures of adherence has frequently been low 
31,32,33. The key differences obtained for each of 
the adherence measures has led to recommen-
dations for simultaneous use of more than one 
method in a bid to improve the performance of 
the final measurement 8,34,35.
Combined measurements should however 
aim to ascertain simultaneously the several di-
mensions of adherence, and not solely the per-
centage of doses taken. In any event, if we accept 
that adherence is composed of the act, process 
and effect of adherence, we require measure-
ments which can reflect as accurately as possible 
these different analytical facets.
A composite adherence score that uses elec-
tronic monitoring, pill counts, and patient self-
reports 36,37 can assess all these facets but may be 
not feasible in many settings. For most settings, 
questionnaires still are the cheapest and most 
feasible option. Non-threatening and non-judg-
mental questions are capable of detecting both 
the act of adhering (through taken/missed doses) 
and the process (through regular/erratic timing 
of medication).
The effect of adherence, which is evidently 
a favorable clinical outcome, warrants further 
discussion.
Although clinical measures are widely used as 
indicators of adherence by physicians in clinical 
contexts 38, few authors used clinical control as 
part of the “deciding rule” to consider the indi-
vidual as adherent in epidemiological study. The 
classical definitions of adherence used in most 
studies do not consider clinical outcomes as a 
component of adherence. In such studies, the 
clinical outcome is commonly used to establish 
correlations between levels of adherence and 
outcome, and to validate the adherence measure-
ment or even establish cut-off points between 
adherents and non-adherents 16,39.
The use of clinical outcomes as an indirect 
measurement of adherence is evidently limited 
by the fact that clinical improvement depends 
not only on correctly taking medication, but on 
several other factors. Among them, the most im-
portant is the non-response whose distinction 
from non-adherence is a crucial matter to the 
clinical approach. From an epidemiological point 
of view, this distinction is also very important in 
clinical trials assessing the efficacy of medicines.
However, the chronic disease treatments that 
are carried out in most health care services es-
tablish their average efficacy beforehand. There-
fore, from an epidemiological point of view the 
measure of ratios and means of adherence does 
not always need to take into account rates of 
non-response. The association between adher-
ence and mortality rates independently of the 
response has already been well established for 
many chronic conditions 40. Another important 
focus of epidemiological studies on adherence is 
the association between adherence rates and the 
level of quality of health care services 41,42.
The most important methodological require-
ment to measures of adherence in epidemiologi-
cal studies is their accuracy. Some self reported 
indicators of outcomes can be useful to improve 
the accuracy of adherence measures.
Blood pressure reading, a simple and easily 
applied measure, was used in an early study on 
adherence to treatment in hypertension. Consid-
ering non-adherents as those reporting non-ad-
herence and presenting uncontrolled blood pres-
sure, the rate of non-adherence increased from 
67.6% to 79.6% 28.
We have recently developed a self-reported 
questionnaire to measure adherence to hyper-
tension treatment. The questionnaire contains 
three questions which sought to assess the three 
dimensions discussed above. The final non-ad-
herence rate is composed of self reported missed 
doses (act of adhering), timing of pill consump-
tion (process of adhering) and the presentation 
of uncontrolled blood pressure (effect of adher-
ing). The rate of non-adherence increased from 
17.4% (for missed doses) to 28.3% (for timing) 
and to 30.7% (for report of uncontrolled arte-
rial pressure). The combined measurement was 
47.73%. Using also a combined measurement as 
a gold standard comprised of pill counting (the 
act), the Morisky et al. 19 questionnaire (process) 
and blood pressure measurement (effect), sensi-
tivity was 63% and the predictive positive value 
was 91% 43.
Self reported clinical outcome, when feasi-
ble, is able to increase sensitivity for non-adher-
ence, i.e. the detection of true non-adherents of 
the questionnaires used in the epidemiological 
studies in the usual health care settings. This is 
an advantage in view of the fact that the major-
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ity of self-reported cases achieve low sensitivity 
coupled with high specificity (since patients who 
state they are non-adherent almost always are 
but not the opposite i.e. patients who state they 
are adherent may not be in many cases).
On the other hand, improving sensitivity can 
increase the proportion of false positives, i.e. er-
roneously considering those who adhere as non-
adherents. This can be, however, an additional 
advantage, since the choice of method should, 
as well as its validity and reliability, be based on 
its usefulness in light of the researcher’s goals. If, 
for instance, we intend to use adherence ratios as 
indicators of the quality of care in health services 
(or the effectiveness of an intervention), overes-
timating the number of non-adherents (through 
false-positive individuals) seems appropriate. 
In any event, the main aim in this situation is to 
identify the greatest number of non-adherents 
possible for subsequent targeting by the health 
care team.
The studies on adherence within the epide-
miological contexts contribute towards the de-
vising of policies and achieving more effective 
managerial and clinical practices. The quality 
of this contribution depends on the quality of 
methodological approaches. However, this also 
depends on the correct interpretation and incor-
poration of findings into practice.
Studies of adherence to AIDS antiretroviral 
treatment in Brazil, for instance, have shown that 
low schooling and missed follow-up are associat-
ed with greater odds of non-adherence 42,43. The 
results led to strong recommendations to AIDS 
related health services for the organization of de-
livering care which prioritizes those groups, pro-
viding for instance, swift medical care to those 
missing appointments, or special activities (such 
as groups, home visits and so forth) for those with 
low schooling.
It should be noted, however, that the asso-
ciations found refer to groups with greater odds 
of non-adherence, not necessarily implying that 
individuals belonging to these groups are neces-
sarily non-adherents. Creating special flowcharts 
for these groups cannot be a substitute for in-
dividual care and, most importantly, should not 
imply discriminatory attitudes to those errone-
ously called “high risk for non-adherence”, as has 
unfortunately been seen in some contexts 44,45. 
In contrast, this entails offering special care to 
those who are most vulnerable, precisely in a bid 
to actively foster equity. This discussion is how-
ever more relevant for the clinical context.
Addressing adherence in the clinical 
context: seeking better care
Whereas epidemiological studies seek to differ-
entiate accurately between adherent and non-
adherent groups, this division is meaningless in 
the realm of individual care. In this context clini-
cal control is the most often used “measure” of 
adherence employed by physicians 46,47.
Indeed, if the patient is doing well, all is well. 
Thus, for instance, in a strategy of “intelligent 
non-adherence” patients rightly conclude they 
may achieve the same therapeutic success while 
reducing the medication prescribed, a fact long 
acknowledged amongst people with hyperten-
sion 48,49. Even recent AIDS treatment studies 
have shown that for some antiretroviral regimens 
there is no need for “almost perfect” adherence 
as early studies had suggested 50.
For health professionals, chiefly the physi-
cian, it is important to assess patient adherence 
when clinical outcome is not as expected. In this 
case, the professional’s impression based on 
questioning the patient is widely used. However, 
the physician’s opinion as a method of measuring 
adherence is classically criticized. Many studies 
have shown high values of disagreement amongst 
adherence rates assessed by professional and 
those self-reported by patients and by electronic 
monitoring 51,52. These studies however, refer to 
differences amongst adherence ratios of groups. 
For this reason, studies measuring adherence in 
the epidemiological context rarely use clinicians’ 
opinions as a method of measurement. When 
used, it is only considered as part of composed 
scales of adherence (once it is recognized that 
the clinicians’ assessments of their patients’ ad-
herence are strongly based on the clinical and 
laboratorial results) 49,50.
Individual care, on the other hand, clearly 
cannot override medical opinion, for risk of un-
dermining the technical basis of medical work, 
grounded in the autonomy of reaching judg-
ments and taking decisions also based on the 
individual meeting with the patient 53. In other 
words, it is impossible for the physician not to 
base their decision on the impression they ac-
quire from contact with the patient.
Obviously, the inherent subjectivity of the 
medical decision can be balanced through ad-
ditional instruments. This highlights when it is 
necessary to differentiate between not-enough 
adherence and non-response.
The usual “objective” adherence measures 
(such as manual or electronic pill count) may 
be used in some clinical settings. However all of 
them have well-known limits of reliability and 
feasibility. Most importantly they can be counter-
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productive since the patients may perceive them 
as intrusive and suggestive of a lack of trust from 
the provider 12,54,55.
In the clinical context of adherence measures 
must be practical, inexpensive and suitable in 
the context of the patient-provider relationship. 
Therefore questionnaires (whose reliability and 
validity had been tested in epidemiological stud-
ies) can be helpful in increasing the objectivity of 
the physician’s decisions 56,57.
However, these questionnaires should be 
viewed as auxiliary instruments and be used 
carefully. To repeatedly measure a patient’s ad-
herence may have some undesirable effects on 
the patient-provider relationship as well as rein-
force the “white coat adherence” effect.
In spite of these limits, it is essential for the 
physician to be aware of patient adherence. To-
gether with the clinical parameters, adherence is 
important to enable therapeutic modifications. 
The exact dose of medication needed to achieve 
the desired clinical outcome has only been well 
established for a few diseases. In the majority 
of cases, the dose required must be adjusted for 
each patient. Therefore in most cases the phy-
sician has to know the patient’s adherence, and 
not “to figure out” whether he/she is “adherent” 
or “non-adherent” but rather to be aware of the 
particular situation each patient is currently ex-
periencing with the prescribed treatment. It is 
also very important to counsel patients in estab-
lishing routines of use, particularly important for 
chronic diseases.
However no adherence “measure” is able to 
render spoken patient reports objective to the 
point of making them totally transparent to the 
physician. This is only possible if the patient-
health team relationship is based on mutual trust 
and truthful dialogue.
It is this very issue that represents the greatest 
promise for discussion on the ideas of compli-
ance and adherence. The notion of adherence 
has attempted to bring into focus the patient’s 
point of view with regard to treatment plans. 
However, while for advocates of “adherence” the 
notion represented an evolution in the meaning 
of considering the autonomy of the patient, more 
radical propositions argue that there is little dif-
ference between adherence and compliance.
Several proposals have already criticized the 
notions of compliance and adherence, proposing 
their replacement by ideas which better reflect 
the need to value the autonomy of the patient in 
relation to the treatment. Examples include no-
tions of collaboration 58, autonomy motivation 59 
and empowerment 60.
By the same token, the Royal Pharmaceutical 
Society of Great Britain 61 suggested substituting 
both terms for the notion of concordance which 
attempts to express the process of prescribing/
taking medicines as a therapeutic partnership 
between physician and patient.
The notion of concordance has become fre-
quently used in studies from the United King-
dom. Its definition has changed over time from 
one which focused on the consultation process, 
to a broader notion which ranges from pre-
scribing communication to patient support in 
medicine taking 62. Recent studies have pointed 
out that concordance is synonymous with nei-
ther compliance nor adherence. For them, the 
notion does not refer to patient’s medicine-
taking behavior, but rather the provider-patient 
interaction 63.
With regard to different theoretical origins, 
all of these new conceptual approaches and par-
ticularly the notion of concordance have been 
sought to acknowledge actively the presence of 
another party – the patient – in the health care 
arena. Therefore they highlight the crucial role 
of communication in the clinical context.
Concerning this point a fruitful proposi-
tion has been disseminated in Brazil. Based on 
the philosophical concept of Care, it proposes 
that health providers revisit their attitudes and 
conceptions, that are oriented in a strictly bio-
medical sense 64,65,66,67,68. It argues that those 
patients’ needs beyond those strictly related to 
clinical control are not effectively incorporated 
into health care process, and continue as barri-
ers to adherence 69. Addressing the issue Ayres 67 
(p. 72-3) argues: “In a consultation, in atten-
tive listening, yet oriented in a purely technical 
sense, elements may arise from patients which are 
deemed as the non-comprehension of instructions 
(...), or disregard for health. In listening (...) which 
does not have technical success as a strict goal 
of the dialogue, the same elements may appear 
as a conflict of values in adopting guidance (...), 
practical obstacles to observance of the prescrip-
tion (...) or simply a mismatch between what [the 
patient] is looking for [in the health service] and 
what is being offered”.
This notion of care understands that those 
“nontechnical” dimensions have to be actively 
considered by the health care provider (and not 
be only informally responded to by means of 
providers’ personal initiatives and compassio-
nate feelings). It argues that that the technical 
success of the treatment depends on a “practi-
cal success” i.e. the capacity of the health care in 
focusing, beyond the clinical outcome, on the 
aspirations of the patients relating to health, 
but also and especially to life more broadly. In 
this sense, it proposes that care must include a 
negotiation of the best possible outcome given 
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the patient’s project of life and well-being at the 
time 65,67,68.
It is almost intuitive to realize that the good 
health provider-patient dialogue is a basic un-
derlying condition for both “concordance” and 
“care” notions. The notion of care however seems 
more useful in helping to understand the issue 
of adherence to treatment in the clinical context 
through criticizing the understanding of treat-
ment as being restricted to an instrumental rela-
tionship between that which holds the best tech-
nique (the physician) and that which is the object 
of this technique (the “patient”).
It seems however, that the best potential of 
this notion of care lies in the recuperation of the 
human side of health work, without diminishing 
the weight of its technical dimension. Evidently, 
work in health shall always have a technical goal: 
we work towards ensuring patients follow treat-
ment and improve their health. However, this 
aim cannot be artificially separated from the hu-
man relationship established in a bid to achieve 
this, nor can the price at which this is achieved 
be ignored.
Epidemiological research on taking medi-
cines can work with different definitions of the 
issue. The usefulness of their contributions pre-
dominately lies in their methodological coher-
ence and accuracy. In the clinical context, recog-
nizing adherence as a dynamic phenomenon 70
and accepting that all chronic disease patients 
have their moments of non-adherence 71 appears 
to be the best approach to care. Moreover, ac-
cepting patient behavior in our relationships with 
patients is also needed. As Bernardini 72 (p. 227) 
says “Would it help to adopt Fred Rogers’ theme, ‘I 
like you just the way you are’, to improve relation-
ships with patients who would then be more likely 
to comply?”.
Resumo
Esta revisão discute conceitos e métodos de avaliação 
da adesão do paciente ao tratamento de saúde, aplicá-
veis para a abordagem epidemiológica e para a abor-
dagem clínica. Na abordagem epidemiológica, a ava-
liação deve ter a melhor acurácia possível. Os ques-
tionários de auto-relato são a opção mais viável na 
maioria dos contextos. Entretanto, a maior parte dos 
questionários apresenta baixa sensibilidade aliada a 
alta especificidade. Sugere-se que o desfecho clínico 
auto-relatado, quando factível, é capaz de aumentar a 
sensibilidade desses questionários. Para a abordagem 
clínica, uma acurada discriminação entre aderentes e 
não aderentes é pouco útil. Para o profissional de saú-
de, é mais importante conhecer a situação particular 
pela qual o paciente está, no momento, passando com 
seu tratamento. Questionários de auto-relato aplica-
dos no contexto clínico podem auxiliar a melhorar a 
objetividade da opinião do profissional. Em qualquer 
caso, contudo, o diálogo paciente-profissional é ainda 
a melhor abordagem para avaliar a adesão, assim co-
mo para prover um bom cuidado.
Cooperação do Paciente; Doença Crônica; Avaliação 
de Resultado de Intervenções Terapêuticas
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